Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2022-04-28 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
2017年特一药业集团股份有限公司可转换公司债券2022年跟踪评级报告
Regulatory Filings
2022-04-28 Chinese
关于可转债转股价格调整的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from a company regarding the adjustment of the conversion price of its convertible bonds. It includes specific details about the bond code, previous and adjusted conversion prices, effective date, and the formula used for adjustment based on dividends and stock issuance. The document is short (1136 characters) and focuses on a capital structure change related to convertible bonds, specifically the adjustment of the conversion price due to dividend distribution. This fits the category of Capital/Financing Update (CAP), as it relates to changes in the company's capital structure and financing instruments. It is not a full financial report, audit, or earnings release, nor is it a regulatory filing or announcement of a report publication. Therefore, the correct classification is CAP with high confidence.
2022-04-28 Chinese
关于可转换公司债券2022年跟踪评级报告的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the tracking credit rating report for a convertible bond issued in 2017 by the company. It references the credit rating agency's report and provides a summary of the rating outcome (AA- rating maintained with stable outlook). The document is short (782 characters) and does not contain the full rating report itself but rather announces the issuance and availability of the report on a website. This fits the pattern of a Regulatory Filing (RNS) as it is a regulatory announcement about a credit rating update, not a full financial report or audit report. It is not an Annual Report, Interim Report, or Audit Report, nor is it a Capital/Financing Update since it does not announce new financing but a rating update. Therefore, the best classification is Regulatory Filings (RNS).
2022-04-28 Chinese
2021年年度权益分派的公告
Notice of Dividend Amount Classification · 100% confidence The document is an announcement regarding the implementation of the 2021 annual equity distribution (dividend) plan approved at the 2021 Annual General Meeting held on April 8, 2022. It details the dividend amount, record date, ex-dividend date, and related adjustments to convertible bond conversion price and stock option exercise price. The document is relatively short (2306 characters) and serves as a formal notice of dividend distribution rather than a full annual report or financial statement. It does not contain comprehensive financial data or management discussion but focuses on dividend payment details and related corporate actions. Therefore, it fits the category of a Notice of Dividend Amount (DIV).
2022-04-28 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is an announcement of the resolution passed at the 26th meeting of the 4th Supervisory Board of 特一药业集团股份有限公司. It specifically mentions the review and approval of the company's 2022 first quarter report by the Supervisory Board, confirming that the report complies with legal and regulatory requirements and is accurate and complete. However, the document itself does not contain the actual financial statements or substantive financial data of the quarterly report; it is a formal announcement of the Supervisory Board's approval of the report. The document length is short (624 characters), and it serves as a formal disclosure of the Supervisory Board's resolution rather than the report itself. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such announcements that do not contain the full report or detailed financial data.
2022-04-27 Chinese
2022年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2022 年第一季度报告全文" which translates to "Full 2022 First Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on non-recurring items. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for the first quarter of 2022. It also mentions that the report is unaudited, which is typical for interim or quarterly reports. The length of the document (over 12,000 characters) and the presence of substantive financial data confirm it is not merely an announcement or a certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2022
2022-04-27 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.